Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 0.85 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.85 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.85 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.85 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.85 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.85 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.85 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720810 | 0.97 | SIGMAR1 (0.84) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6419685 | 0.92 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6422901 | 0.88 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7374537 | 0.86 | SIGMAR1 (0.67) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6507964 | 0.85 | SIGMAR1 (0.72) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6716979 | 0.84 | SIGMAR1 (0.67) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7378097 | 0.83 | SIGMAR1 (0.61) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6724469 | 0.82 | SIGMAR1 (0.76) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6720780 | 0.81 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6719803 | 0.81 | SIGMAR1 (0.78) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | disclosed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | SIGMAR1 3775/4885GRIN2D 3242/4885GRIN3B 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.